The most prominent mRNA vaccines being used across countries against COVID-19 are manufactured by Pfizer-BioNtech and Moderna. (Reuters)
A vaccine focused directly on the Omicron variant would also protect against successful infection with a strain that has proven to be highly infectious.
- AFP
- Last Update:11 January 2022, 11:20 IST
- What should I follow:
The company’s chief said on Monday that Pfizer expects to have a COVID-19 vaccine targeting the Omicron variant ready in March. Pfizer Chief Executive Officer Albert Boerla told CNBC that Pfizer is already manufacturing supplements because of the keen interest from governments, as officials count the heavy Covid-19 infection, with a large number of “breakthroughs” on Omicron. cases are included.
“This vaccine will be ready in March,” Bourla told the network. “I don’t know if we’ll need it. I don’t know if it will be used.”
Bourla said the current regime of two vaccine shots and one booster provided “reasonable” protection against serious health effects from Omicron.
But a vaccine focused directly on the Omicron variant would also protect against successful infection with a strain that has proven to be highly infectious, but has also resulted in many mild or asymptomatic cases.
In a separate interview with CNBC on Monday, Moderna CEO Stephen Bunsell said the company is developing a booster that can address Omicron and other emerging strains in the fall of 2022.
“We are discussing with public health leaders around the world what we think are the best strategies for potential boosters for fall 2022,” Bansal told the network. “We need to be careful to try to stay ahead of the virus. And not behind the virus.”
read all breaking news, today’s fresh news And coronavirus news Here.
,